Press Release
27 September 2018
Immunicum AB (publ) Announces Upcoming Presentations at Conferences in October
Immunicum AB (publ; IMMU.ST) today announced that Company leadership will present at upcoming regulatory affairs, industry and scientific conferences in October.
The Organization for Professionals in Regulatory Affairs (TOPRA) Annual Symposium 2018 -Human Medicines Section
Date: October 1 - 3, 2018
Presentation Time: October 3, 12:00 pm Central European Time
Presentation Title: An SME regulatory ATMP case study
Presenter: Margareth Jorvid, Head of Regulatory and QA
Venue: Quality Hotel Globe, Stockholm, Sweden
Sachs 18th Annual Biotech in Europe Forum
Date: October 4 - 5, 2018
Presentation Time: October 5, 2018, 10:15 am Central European Time
Presentation Title: Company Overivew
Panel: Oncology I - BD&L Panel Friday, October 5, 11:15 am Central European Time
Presenter and Panelist: Carlos de Sousa, CEO
Venue: Congress Center Basel, Switzerland
ESMO 2018 Congress
Date: October 19 - 23, 2018
Poster Presentation Time: October 22, 2018, 12:45 pm - 1:45 pm Central European Time
Poster No. and Title: 440P; Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect
Presenter: Alex Karlsson-Parra, CSO
Venue: Messe Munich, Munich, Germany
For more information, please contact:
Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Michaela Gertz, CFO, Immunicum
Telephone: +46 70 926 17 75
E-mail: ir@immunicum.com
Media Relations
Gretchen Schweitzer and Jacob Verghese
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com
About Immunicum AB (publ)
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm www.immunicum.com
